Search results for " Function"

showing 10 items of 9395 documents

The induction of hepatic microsomal metabolism in rats following acute administration of a mixture of polybrominated biphenyls.

1976

Abstract Firemaster BP6, a mixture of polybrominated biphenyls (PBBs), was administered to female Sprague-Dawley rats (170–180 g) as a single ip injection at 25 and 150 mg/kg. Other animals received phenobarbital (PB), 3-methylcholanthrene (3MC), or PB and 3MC together. Animals were killed at intervals of 12, 24, 48, 192, and 336 hr after treatment with PBBs, or 24 hr after PB, MC, or PB-MC, and various hepatic microsomal parameters were measured. After 150 mg/kg of PBBs, cytochrome P450 concentrations reached a maximum by 48 hr (225% of control), then remained elevated through 336 hr. A similar pattern of induction was observed for epoxide hydratase and aniline hydroxylase activities. In c…

medicine.medical_specialtyTime FactorsPolybrominated BiphenylsIn Vitro TechniquesToxicologyMixed Function OxygenasesInternal medicinemedicineAnimalsEnzyme inducerAniline HydroxylasePharmacologychemistry.chemical_classificationChromatographybiologyBiphenyl CompoundsBody WeightCytochrome P450MetabolismEthylmorphineRatsEnzymeEndocrinologychemistryLiverEnzyme InductionPhenobarbitalbiology.proteinMicrosomeMicrosomes LiverPhenobarbitalFemalemedicine.drugMethylcholanthreneToxicology and applied pharmacology
researchProduct

Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function

1978

Infusions of 3.5% isocyanate cross-linked polypeptide solution 500 ml were given to 52 patients with normal or impaired renal function: glomerular filtration rate (GFR)=0–133 ml/min. The serum concentration and urinary excretion of hydroxyproline were measured and the equivalent polypeptide concentrations were calculated from the results. In patients with normal renal function (GFR>90 ml/min) the proportion of polypeptide excreted in the urine up to 12 h was 45.4±2.6% ( $$\bar X$$ ±SEM), up to 24 h 47.7±2.9% and up to 48 h 49.3±3.4%. In patients with moderate renal insufficiency (GFR=30–90 ml/min) there was no decrease in polypeptide excretion and even in patients with more serious impairme…

medicine.medical_specialtyTime FactorsUrinary systemPlasma SubstitutesRenal functionUrine030204 cardiovascular system & hematologyurologic and male genital diseasesExcretion03 medical and health sciencesHydroxyprolinechemistry.chemical_compound0302 clinical medicinePharmacokineticsRenal Dialysis030202 anesthesiologyInternal medicinemedicineHumansPharmacology (medical)CyanatesPharmacologyChemistryHalf-lifeGeneral Medicine3. Good healthKineticsEndocrinologyKidney DiseasesPeptidesHaemaccelGlomerular Filtration RateHalf-LifeEuropean Journal of Clinical Pharmacology
researchProduct

Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function

2013

After entering the blood, bisphosphonates are immediately bound to bone or excreted unchanged by the kidney. During renal excretion about 0.5% of administrated dosage remains in kidney tissue. The renal tissue level of bisphosphonates (RTL) decreases over time and remains at about 0.15% after 3weeks, but the influence of renal insufficiency (RI) is unclear.We investigated the influence of mild to moderate RI on RTL of ibandronate (IBD). First a method for determination of RTL was implemented and validated. We measured RTL in rats with normal renal function (SHAM) and after unilateral nephrectomy (UNX). In each case one SHAM and one UNX groups received one or alternatively 9 times every 3wee…

medicine.medical_specialtyTime FactorsUrologyKidneyToxicologySeverity of Illness IndexImpaired renal functionNormal renal functionmedicineAnimalsTissue DistributionRenal InsufficiencyRats WistarIbandronic AcidPharmacologyKidneyBone Density Conservation AgentsDiphosphonatesbusiness.industryRenal tissueUnilateral nephrectomyRatsSurgeryDisease Models Animalmedicine.anatomical_structureRenal physiologyFemalebusinessHalf-LifeJournal of Pharmacological and Toxicological Methods
researchProduct

A score model for the continuous grading of early allograft dysfunction severity

2014

Early allograft dysfunction (EAD) dramatically influences graft and patient outcomes. A lack of consensus on an EAD definition hinders comparisons of liver transplant outcomes and management of recipients among and within centers. We sought to develop a model for the quantitative assessment of early allograft function [Model for Early Allograft Function Scoring (MEAF)] after transplantation. A retrospective study including 1026 consecutive liver transplants was performed for MEAF score development. Multivariate data analysis was used to select a small number of postoperative variables that adequately describe EAD. Then, the distribution of these variables was mathematically modeled to assig…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentLiver transplantationModels BiologicalSeverity of Illness IndexDecision Support TechniquesLiver diseasePredictive Value of TestsRisk FactorsInternal medicineSeverity of illnessmedicineHumansInternational Normalized RatioBlood CoagulationProportional Hazards ModelsRetrospective StudiesPrincipal Component AnalysisTransplantationHepatologyProportional hazards modelbusiness.industryGraft SurvivalReproducibility of ResultsAlanine TransaminaseBayes TheoremBilirubinRetrospective cohort studyClinical Enzyme Testsmedicine.diseaseLiver TransplantationSurgeryTransplantationTreatment OutcomeNonlinear DynamicsPredictive value of testsMultivariate AnalysisSurgeryLiver functionPrimary Graft DysfunctionbusinessBiomarkersLiver Transplantation
researchProduct

Nonroutine Use of Intra-Aortic Balloon Pump in Cardiogenic Shock Complicating Myocardial Infarction With Successful and Unsuccessful Primary Percutan…

2018

Abstract Objectives The authors sought to compare outcomes of patients with myocardial infarction and cardiogenic shock (CS) treated with percutaneous coronary intervention (PCI) with or without intra-aortic balloon pump (IABP) support according to final epicardial flow in the infarct-related artery. Background A routine use of IABP is contraindicated in patients with myocardial infarction and CS. There are no data regarding the subpopulation of patients who may benefit from such support besides patients with mechanical complications of myocardial infarction. Methods Prospective nationwide registry data of patients with myocardial infarction and CS treated with PCI between 2003 and 2014 wer…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentShock Cardiogenicprimary PCI030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsInternal medicinemedicineHumansProspective StudiesRegistriescardiovascular diseases030212 general & internal medicineMyocardial infarctionIABPNon-ST Elevated Myocardial InfarctionIntra-aortic balloon pumpIntra-Aortic Balloon Pumpingbusiness.industryCardiogenic shockHazard ratiocardiogenic shockPercutaneous coronary interventionRecovery of FunctionThrombolysismedicine.diseaseTreatment Outcomesurgical procedures operativemyocardial infarctionConventional PCICardiologyST Elevation Myocardial InfarctionPolandCardiology and Cardiovascular MedicinebusinessTIMIJACC-Cardiovascular Interventions
researchProduct

Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

2021

Aims Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients …

medicine.medical_specialtyTranscatheter aorticVentricular Function Leftlaw.inventionTranscatheter Aortic Valve Replacementchemistry.chemical_compoundRandomized controlled trialGlucosideslawInternal medicineDiabetes mellitusmedicineHumansProspective StudiesDapagliflozinBenzhydryl CompoundsHeart FailureEjection fractionbusiness.industryStroke VolumeAortic Valve Stenosismedicine.diseaseStenosisTreatment OutcomechemistryHeart failureAortic ValveCardiologyCardiology and Cardiovascular MedicinebusinessKidney diseaseEuropean journal of heart failureReferences
researchProduct

Intensive Care Management of Head-Injured Patient

2019

Traumatic brain injury (TBI) plays an important role for the prognosis of multiple injured patients. Severely injured patients require intensive care treatment to support organ function and to maintain normal brain physiology. Optimal treatment is a cornerstone for good outcome. Therefore, in addition to general principles and concepts of modern intensive care medicine, special brain-specific aspects need to be addressed in these patients. Essential aspects of physiological regulation of cerebral perfusion and intracranial pressure as well as recent publications are reviewed as basis for current trends in the management of TBI patients. Focusing on single parameters such as intracranial pre…

medicine.medical_specialtyTraumatic brain injurybusiness.industryIntensive care managementOrgan functionMultimodal therapymedicine.diseaseCerebral oxygenationmedicineCerebral perfusion pressureIntensive care medicinebusinessIntensive care treatmentIntracranial pressure
researchProduct

Treatment of clinically localized renal tumors in the elderly

2011

There are several options for treating clinically localized renal tumors in the elderly, ranging from active surveillance to radical nephrectomy. Reduced renal function is associated with increased cardiovascular mortality, so maintaining renal function is of the utmost importance. Personalized therapy should be based on tumor location, comorbidities and general health status rather than tumor size and patient age.

medicine.medical_specialtyTumor sizebusiness.industryUrologymedicine.medical_treatmentUrologyRenal functionurologic and male genital diseasesmedicine.diseaseNephrectomymedicineGeneral healthTumor locationPersonalized therapybusinessKidney cancerCardiovascular mortalityNature Reviews Urology
researchProduct

Shared Genetic and Environmental Effects on Strength and Power in Older Female Twins

2005

Purpose: This study examined the relative contribution of genetic and environmental effects on maximal leg extensor power and also investigated whether leg extensor power and maximum voluntary isometric knee extensor strength share a genetic component. Methods: Muscle functions were measured as part of the Finnish Twin Study on Aging in 101 monozygotic (MZ) and 116 dizygotic (DZ) female twin pairs aged 63–76 yr. Leg extensor power was measured using the Nottingham Leg Extensor Power Rig and maximum voluntary isometric knee extensor strength using an adjustable dynamometer chair. The analyses were carried out using the maximum likelihood method in Mx-program on the raw data set. Results: A b…

medicine.medical_specialtyTwinsPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseBiologyCohort StudiesTwins DizygoticmedicineHumansKneeOrthopedics and Sports MedicineExerciseFinlandAgedKnee extensorsDynamometerMusclesTwins MonozygoticMiddle AgedMuscle functionsHeritabilitymusculoskeletal systemTwin studyPower (physics)Environmental effectLower ExtremityPhysical therapyFemaleMedicine & Science in Sports & Exercise
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct